Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: Current recommendations from the Safety Pharmacology Society

Journal of Pharmacological and Toxicological Methods

Volumn 65, Issue 3, 2012, Pages 93-101

  Leishman, D J ^a   Beck, T W ^a   Dybdal, N ^b   Gallacher, D J ^a   Guth, B D ^c   Holbrook, M ^d   Roche, B ^e   Wallis, R M ^d  

^a Lilly ^*  (Belgium)

^b GENENTECH INC   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Cardiovascular; Dogs; Methods; Monkeys; QT Prolongation; Safety Pharmacology

Indexed keywords

ATORVASTATIN; SIBUTRAMINE; TORCETRAPIB;

ADVERSE OUTCOME; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CEREBROVASCULAR ACCIDENT; CIRCADIAN RHYTHM; CLINICAL EVALUATION; CLINICAL PRACTICE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESEARCH; DRUG SAFETY; DRUG SENSITIVITY; ELECTROCARDIOGRAPHY MONITORING; HEART ARRHYTHMIA; HEART INFARCTION; HEART RATE; HEMODYNAMIC PARAMETERS; HUMAN; LONG TERM CARE; NONHUMAN; OBESITY; PREDICTIVE VALUE; QT PROLONGATION; QUALITATIVE ANALYSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TACHYCARDIA; TELEMETRY;

ANIMALS; CARDIOVASCULAR SYSTEM; DRUG DISCOVERY; DRUG TOXICITY; HUMANS; PHARMACEUTICAL PREPARATIONS;

CANIS FAMILIARIS;

EID: 84861481556     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2011.08.006     Document Type: Article

References (54)

1. Anon ICHS7A. ICH Guidance 2000, 1-10.
2. Anon ICH S7B November 2005 Step 5. ICH Guidance 2005, 1-13.
3. Anon ICH E14 November 2005. ICH Guidance 2005, 1-20.
4. Anon Guidance for industry diabetes mellitus - Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes 2008, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER).
5. Anon Draft guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus 2010, Committee for Medicinal Products for Human Use (CHMP), CPMP/EWP/1080/00 Rev. 1.
6. Atterson P., Voss K., Kopp G. Occurrence and variance of ECG waveform abnormalities in canines and non-human primates: What is considered normal?. Journal of Pharmacological and Toxicological Methods 2010, 62:e27.
7. Averill K.H., Lamb L.E. Electrocardiographic findings in 67,375 asymptomatic subjects. I. Incidence of abnormalities. The American Journal of Cardiology 1960, 6:76-83.
8. Bethge K.-P., Bethge D., Meiners G., Lichtlen P. Incidence and prognostic significance of ventricular arrhythmias in individuals without detectable heart disease. European Heart Journal 1983, 4:338-346.
9. Bjerregaard P. Premature beats in healthy subjects 40-79years of age. European Heart Journal 1982, 3:493-503.
10. Brodsky M., Wu D., Denes P., Kanakis C., Rosen K.M. Arrhythmias documented by 24hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. The American Journal of Cardiology 1977, 39:390-395.
11. Cavero I. Cardiovascular system assessment best practices: A Safety Pharmacology Society meeting. Expert Opinion on Drug Safety 2010, 9:855-866.
12. Chamepeoux P., Martel E., Fowler J.S.L., Maurin A., Sola L., Jude S., et al. Calculation of QT shift in non clinical safety pharmacology studies. Journal of Pharmacological and Toxicological Methods 2009, 59:73-85.
13. Chiang A., Bass A., Cooper M., Engwall M., Menton R., Thomas K. ILSI-HESI cardiovascular safety subcommittee dataset: An analysis of the statistical properties of QT interval and rate-corrected QT interval (QTc). Journal of Pharmacological and Toxicological Methods 2007, 56:95-102.
14. Chiang A., Holdsworth D., Leishman D. A one-step approach to the analysis of the QT interval in conscious telemetrized dogs. Journal of Pharmacological and Toxicological Methods 2006, 54:183-188.
15. Chiang A., Smith W., Main B., Sarazan R. Statistical power analysis for hemodynamic cardiovascular safety pharmacology studies in beagle dogs. Journal of Pharmacological and Toxicological Methods 2004, 50:121-130.
16. Cools F., Janssens S., Vanlommel A., Teisman A., Towart R., Gallacher D. ECG arrhythmias in non-implanted vs. telemetry-implanted dogs: Need for screening before and sufficient recovery time after implantation. Journal of Pharmacological and Toxicological Methods 2011, 64:60-67.
17. Detweiler D.K. The dog electrocardiogram: A critical review. Comprehensive electrocardiography 1988, 1268-1329. New York. P.W. MacFarlane, T.D.V. Lawrie (Eds.).
18. Detweiler D.K. Electrocardiography in toxicological studies. Comprehensive toxicology volume 6 1997, 95-116. New York. I. Glenn Sipes, A. McQueen, A. Jay Gandolfi (Eds.).
19. Gauvin D.V., Tilley L.P., Smith F.W., Baird T.J. Electrocardiogram, hemodynamics, and core body temperatures of the normal freely moving cynomolgus monkey by remote radiotelemetry. Journal of Pharmacological and Toxicological Methods 2006, 53:140-151.
20. Gauvin D.V., Tilley L.P., Smith F.W., Baird T.J. Spontaneous cardiac arrhythmias recorded in three experimentally- and drug-naive laboratory species (canine, primate, swine) during standard pre-study screening. Journal of Pharmacological and Toxicological Methods 2009, 1-5.
21. Guth B., Bass A., Briscoe R., Chivers S., Markert M., Siegl P., et al. Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies. Journal of Pharmacological and Toxicological Methods 2009, 60:107-116.
22. Hanson L., Bass A., Gintant G., Mittelstadt S., Rampe D., Thomas K. ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation. Journal of Pharmacological and Toxicological Methods 2006, 54:116-129.
23. Holzgrefe H.H., Cavero I., Gleason C.R. Analysis of the nonclinical telemetered ECG: Impact of logging rate and RR bin width in the dog and cynomolgus monkey. Journal of Pharmacological and Toxicological Methods 2007, 56:34-42.
24. Holzgrefe H.H., Cavero I., Gleason C.R., Warner W.A., Buchanan L.V., Gill M.W., et al. Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys. Journal of Pharmacological and Toxicological Methods 2007, 55:159-175.
25. Ilson B.E. Cardiovascular monitoring in normal healthy adults: A literature review and recommendations for the reporting of disturbances of cardiac rhythm. American Journal of Therapeutics 1995, 2:893-899.
26. Jonker D., Kenna L., Leishman D., Wallis R., Milligan P., Jonsson E. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition. Clinical Pharmacology and Therapeutics 2005, 77:572-582.
27. + current by dofetilide. Circulation Research 1993, 72:75-83.
28. Klumpp A., Trautmann T., Markert M., Guth B. Optimizing the experimental environment for dog telemetry studies. Journal of Pharmacological and Toxicological Methods 2006, 54:141-149.
29. Lau C., Freedman A., Fleming S., Malik M., Camm A., Ward D. Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rate. Cardiovascular Research 1988, 22:67.
30. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet 2002, 306:1903-1913.
31. Littell R.C., Milliken G.A., Stroup W.W., Russell D., Wolfinger R.D., Schabenberber O. SAS for mixed models 2006, Second Edition.
32. Mellor H.R., Bell A.R., Valentin J.-P., Roberts R.R.A. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicological Sciences 2011, 120:14-32.
33. Nakaya H., Hashimoto K. QT PRODACT: Database construction for the evaluation of the risk of QT interval prolongation by drugs in Japan. Journal of Pharmacological Sciences 2005, 99:421.
34. Nissen S., Tardif J., Nicholls S., Revkin J., Shear C., Duggan W., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. The New England Journal of Medicine 2007, 356:1304.
35. Ochsner A.J. Cardiovascular and respiratory responses to ketamine hydrochloride in the rhesus monkey (Macaca mulatta). Laboratory Animal Science 1977, 27:69-71.
36. Oguchi Y., Hamlin R.L. Rate of change of QT interval in response to a sudden change in the heart rate in dogs. American Journal of Veterinary Research 1994, 55:1618-1623.
37. Ollerstam A., Persson A., Visser S., Fredriksson J.M., Forsberg T., Nilsson L., et al. A novel approach to data processing of the QT interval response in the conscious telemetered beagle dog. Journal of Pharmacological and Toxicological Methods 2007, 55:35-48.
38. Ollerstam A., Visser S., Persson A., Eklund G., Nilsson L., Forsberg T., et al. Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs. Journal of Pharmacological and Toxicological Methods 2006, 53:174-183.
39. Pagel P.S., Kampine J.P., Schmeling W.T., Warltier D.C. Influence of volatile anesthetics on myocardial contractility in vivo: Desflurane versus isoflurane. Anesthesiology 1991, 74:900-907.
40. Polakowski J.S., King A.J., Campbell T.J., Nelson R.A., Preusser L.C., Kempf-Grote A.J., et al. Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs. Journal of Cardiovascular Pharmacology 2009, 54:543-551.
41. Redfern W.S., Ewart L., Hammond T.G., Bialecki R., Kinter L., Lindgren S., et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle (Abstract 1081). Toxicologist 2010, 114:231.
42. Sarazan R.D., Mittelstadt S., Guth B., Koerner J., Zhang J. Cardiovascular function in nonclinical drug safety assessment: current issues and opportunities. International Journal of Toxicology 2011, 30:272-286.
43. Sasaki H., Shimizu N., Suganami H., Yamamoto K. QT PRODACT: Inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeys. Journal of Pharmacological Sciences 2005, 99:513-522.
44. Scheen A.J. Cardiovascular risk-benefit profile of sibutramine. American Journal of Cardiovascular Drugs 2010, 10:321-334.
45. Schmeling W.T., Warltier D.C., Mcdonald D.J., Madsen K.E., Atlee J.L., Kampine J.P. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesthesia and Analgesia 1991, 72:137-144.
46. Sivarajah A., Collins S., Sutton M., Regan N., West H., Holbrook M., et al. Cardiovascular safety assessments in the conscious telemetered dog: Utilisation of super-intervals to enhance statistical power. Journal of Pharmacological and Toxicological Methods 2010, 62:12-19.
47. Soloviev M.V., Hamlin R.L., Barrett R.M., Chengelis C.P., Schaefer G.J. Different species require different correction factors for the QT interval. Cardiovascular Toxicology 2006, 6:145-157.
48. Stevens J.L., Baker T.K. The future of drug safety testing: Expanding the view and narrowing the focus. Drug Discovery Today 2009, 14:162-167.
49. Stinson J.C., Pears J.S., Williams A.J., Campbell R.W. Use of 24h ambulatory ECG recordings in the assessment of new chemical entities in healthy volunteers. British Journal of Clinical Pharmacology 1995, 39:651-656.
50. Tattersall M.L., Dymond M., Hammond T., Valentin J.-P. Correction of QT values to allow for increases in heart rate in conscious Beagle dogs in toxicology assessment. Journal of Pharmacological and Toxicological Methods 2006, 53:11-19.
51. Toyoshima S., Kanno A., Kitayama T., Sekiya K., Nakai K., Haruna M., et al. QT PRODACT: In vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. Journal of Pharmacological Sciences 2005, 99:459-471.
52. Ulloa H., Houston B., Altrogge D. Arrhythmia prevalence during ambulatory electrocardiographic monitoring of Beagles. American Journal of Veterinary Research 1995, 56:275-281.
53. Van Deuren B., Van Ammel K., Somers Y., Cools F., Straetemans R., van der Linde H.J., et al. The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: A versatile in vivo model in cardiovascular safety research. Journal of Pharmacological and Toxicological Methods 2009, 60:11-23.
54. Wallis R. Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. British Journal of Pharmacology 2010, 159:115-121.